Optimizing Oligonucleotide Therapeutics: A Model-Informed Drug Development Perspective.
Mathematical modeling frameworks help researchers design more efficient trials for RNA-based drugs treating rare diseases where few patients exist.
This FDA-affiliated review in Clinical and Translational Science outlines how model-informed drug development frameworks can accelerate and optimize oligonucleotide therapeutics across antisense, siRNA, and aptamer modalities — especially critical for rare disease trials with limited patient populations. Specific guidance on tissue distribution modeling, pharmacodynamic response, and adaptive trial design is provided.
What the study was
- Study design
- Narrative review (model-informed drug development perspective)
- Population
- Patients with rare diseases or conditions amenable to oligonucleotide therapeutics
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Clinical and Translational Science
Why it surfaced
FDA-affiliated authors (Clin Transl Sci); relevant to rare disease oligonucleotide development pipeline; primarily technical/methodology review; limited direct clinical impact.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.